title: Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.
abstract: Nitrogen-containing bisphosphonates (BPs) are antiresorptive drugs used for the treatment of metabolic bone diseases. Bone marrow stromal cells such as mesenchymal stem cells (MSCs) and MSC-derived osteoblasts that originate from MSCs are known to regulate osteoclast differentiation and activation via the expression of receptor activator of NF-κB ligand (RANKL). Although the effects of nitrogen-containing BPs on osteoclasts and osteoblasts have been well investigated, their effects in MSCs have not been clarified. In this study, we investigated the effects of risedronate (RIS), a nitrogen-containing BP, on osteoblast differentiation, RANKL expression and apoptosis in human and rat MSCs. RIS suppressed the formation of mineralized nodules and mRNA expression of differentiation marker genes such as bone sialoprotein and osteocalcin in MSC-derived osteoblasts. The RANKL expression induced by 1,25-(OH)(2) vitamin D(3) was not affected by RIS in human MSC-derived osteoblasts. In addition, treatment with high-concentration RIS induced chromatin condensation, an apoptosis feature, in MSCs. RIS-induced chromatin condensation was suppressed by a pan-caspase inhibitor zVAD-FMK and a cell-permeable isoprenoid analogue geranylgeraniol. These results indicate that RIS suppressed osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis and suggest that the antiresorptive effect of RIS is not mediated by a decrease in the RANKL expression in MSC-derived osteoblasts.
authors.affiliation: Department of Cytology and Histology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan. fujita00@md.okayama-u.ac.jp
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Fujita
authors.forename: Kazuko
authors.initials: K
authors.lastname: Kurokawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ogino
authors.forename: Mio
authors.initials: M
authors.lastname: Ono
authors.forename: Masanao
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Oka
authors.forename: Tohru
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Naoya
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tanaka
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ogawa
authors.forename: Etsuko
authors.initials: E
authors.lastname: Suzaki
authors.forename: Kozo
authors.initials: K
authors.lastname: Utsumi
authors.forename: Junzo
authors.initials: J
authors.lastname: Sasaki
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects*; D002478:Cells, Cultured; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects*; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D053245:RANK Ligand / Q000032:analysis*; D051381:Rats; D000068296:Risedronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000068296:Risedronic Acid; D012968:Etidronic Acid